

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): March 20, 2018

**MOTUS GI HOLDINGS, INC.**

*(Exact name of registrant as specified in its charter)*

**Delaware**  
*(State or other jurisdiction  
of incorporation)*

**001-38389**  
*(Commission  
File Number)*

**81-4042793**  
*(IRS Employer  
Identification No.)*

**1301 East Broward Boulevard, 3rd Floor**  
**Ft. Lauderdale, FL**  
*(Address of principal executive offices)*

**33301**  
*(Zip Code)*

Registrant's telephone number, including area code: **786 459 1831**

**Not Applicable**

*(Former name or former address, if changed since last report.)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 7.01. Regulation FD Disclosure.**

Motus GI Holdings, Inc. (the “Company”) is using the slides attached hereto in connection with management presentations to describe its business. A copy of the investor presentation is available at the “Investors – Company Info - Presentations” section of the Company’s website at <https://ir.motusgi.com/presentations>, and is attached hereto as Exhibit 99.1.

The content of the Company’s website is not incorporated by reference in this Current Report on Form 8-K.

The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by a specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) The following exhibit is furnished with this report:

<u>Exhibit No.</u>	<u>Description</u>
99.1	<a href="#"><u>Investor Presentation.</u></a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MOTUS GI HOLDINGS, INC.**

Dated: March 20, 2018

By: /s/ Mark Pomeranz

Name: Mark Pomeranz

Title: President and Chief Executive Officer

---

**EXHIBIT INDEX**

<u>Exhibit No.</u>	<u>Description</u>
99.1	<a href="#"><u>Investor Presentation.</u></a>

---





# Developing Breakthrough Solutions for Endoscopy

MARCH 2018



## FORWARD-LOOKING STATEMENTS

This presentation contains certain forward-looking statements, including those relating to the Company's product development, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. The Company has made every reasonable effort to ensure the information and assumptions on which these statements are based are current, reasonable and complete. However, a variety of factors, many of which are beyond the Company's control, affect the Company's operations, performance, business strategy and results and there can be no assurances that the Company's actual results will not differ materially from those indicated herein. Additional written and oral forward-looking statements may be made by the Company from time to time in filings with the Securities and Exchange Commission (SEC) or otherwise. The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to,

"expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

## OVERVIEW

FDA-cleared flagship product for colonoscopy – Pure-Vu®

45M endoscopy procedures worldwide annually

Driving clinical data collection to maximize market value

Benefiting patients, physicians and payers

Multiple product expansion opportunities

Team with proven track record

**Motus GI Holdings, Inc.**  
is a medical technology company  
dedicated to improving endoscopy  
outcomes and experiences




# POTENTIAL TO ADDRESS SIGNIFICANT UNMET CLINICAL NEEDS

Targeting Average Selling Price (ASP) of \$250 Per Procedure Disposable Kit

Initial Pure-Vu® Market Opportunity



Broad Market Launch



Targeting Multi-billion Dollar Market Opportunity

Colorectal cancer (CRC)	Inflammatory bowel disease (IBD)	Anemia (lower)	Esophageal cancer
Lower GI bleeds	Irritable bowel syndrome (IBS)	Anemia (upper)	Upper GI bleeds

1: [https://www.cdc.gov/cancer/dcp/research/articles/crc\\_screening\\_model.htm](https://www.cdc.gov/cancer/dcp/research/articles/crc_screening_model.htm)  
 2: iData Research, US Gastrointestinal Endoscopic Devices Market 2014 (Forecasted to 2020) – MedSuite





PLAY VIDEO >

## PURE-VU® OVERVIEW

Initial indication for use in “poorly prepped” colons

Highly efficient pulsed vortex irrigation to break up colon content

Sensing technology to prevent clogging during evacuation

Easy-to-load – integrates easily with current scopes

Closed system manages waste and odor

Strong intellectual property



## PROBLEMS WITH CONVENTIONAL COLONOSCOPY PREP

**57%** of Patients Cite Fear of Bowel Prep as #1 Deterrent of Procedure<sup>1</sup>



### Clear Liquid Diet

Complications with fasting



### Potent Prep – 4L

Awful taste and large volume



### Repeated Visits

Cramping/discomfort



### Missed Work

Work disrupted for 1 to 2 days



**Reduced Detection Rate**  
High failure rate in ~23% of procedures require repeat <3 years<sup>2</sup>

**Colon Cleanliness Drives Procedure Effectiveness**

# PURE-VU® IMPROVES COLONOSCOPY EXPERIENCE

## Micro-Prep

Able to Eat



Low Residue Diet  
(eggs, toast, pasta, etc.)



OTC Mild Laxative



10 oz. bottle  
(magnesium citrate)



**PURE-VU**®  
by MOTUS<sup>GI</sup>

**Company Working to Expand Pure-Vu Indication  
to Actively Promote Micro-Prep Capabilities**

## GO-TO-MARKET STRATEGY: TARGETING LARGE SEGMENTS WITH CLEAR VALUE PROPOSITION

### Market Segments

### Global Opportunity

1

#### **In-Patients: Improving Outcomes and Costs**

Value: Lower costs, speed diagnosis, DRG-based reimbursement

Key populations: Lower GI bleeds; Elderly, Comorbidities, VA patients

**4.1M<sup>1</sup>**

Procedures WW Annually

2

#### **Out-Patients: High Medical Need / Difficult to Prep**

Value: Eliminates repeat procedures, improves diagnosis

Key populations: Diabetes, Obesity, Elderly, Opioids, CRC survivors, etc.

**5.7M<sup>2</sup>**

Procedures WW Annually

3

#### **Out-Patients: Driving Quality and Patient Satisfaction**

Value: Micro-Prep, higher confidence, no lost work

Key populations: Market research shows patients motivated to pay

**19.6M<sup>3</sup>**

Procedures WW Annually

1: IIRA Healthcare Research & Analytics - Market Research, May 2015

2: Hassan C. et al., Clinical Gastroenterology and Hepatology, 2012;10:301-306

3: Lieberman D.A. et al., American Society for Gastrointestinal Endoscopy, Vol 62, No. 6:2003

## IN-PATIENT COLONOSCOPY REPRESENTS SIGNIFICANT UNMET NEED

*Existing DRG-Based Reimbursement Creates Potential for Strong Economic Incentive to Adopt Pure-Vu as Standard of Care*



Global Market Opportunity Represents 4.1 Million Procedures Annually<sup>2</sup>

# IN-PATIENTS STUDIES: IMPROVING OUTCOMES AND COSTS

Reliably and Predictably Move Patients Through System to Successful Exam

Study	Q1 2018	Q2 2018	Q3 2018	Q4 2018	Objective
REDUCE Study - multicenter in-patient prospective trial	Results Expected Q4 2018				<ul style="list-style-type: none"> <li>• Supports significant cost avoidance</li> <li>• Drives hospital value analysis committees</li> </ul>
Lower GI Bleeds			Results Expected Q2 2019		<ul style="list-style-type: none"> <li>• Accelerated diagnosis</li> <li>• Supports key hospital quality metrics</li> </ul>
Veterans Administration - Inadequate Prep Patients			Results Expected H2 2019		<ul style="list-style-type: none"> <li>• Opens large VA opportunity</li> </ul>



## Colon Cleanliness Directly Correlates to Quality of Exam

**Primary Endpoint**  
Improvement in colon cleanliness (BBPS)

**Secondary Endpoints**  
Cost savings and quality metrics






## OUT-PATIENT: HIGH MEDICAL NEED / DIFFICULT TO PREP



Global Market Opportunity Represents 5.7 Million Procedures Annually<sup>2</sup>

## OUT-PATIENT: PATIENTS HIGHLY MOTIVATED FOR BETTER EXPERIENCE

- Patient Out-of-Pocket Pay Creates New High Margin Revenue Source for Physician
- Allows the Ability to Preform Cases Later in the Day



Global Market Opportunity Represents 19.6 Million Procedures Annually<sup>2</sup>

## OUT-PATIENTS STUDIES: DRIVING QUALITY AND PATIENT SATISFACTION

### Supports Reimbursement and Enables Micro-prep DTC Marketing

Study	Q1 2018	Q2 2018	Q3 2018	Q4 2018	Objective
High Medical Need / Difficult to Prep Populations			Results Expected H2 2019		<ul style="list-style-type: none"> <li>• Supports reimbursement</li> </ul>
Prep Optimization	Results Expected Q2 2018				<ul style="list-style-type: none"> <li>• Guides micro-prep indication trial (Low residue diet: eggs, toast, pasta, etc.)</li> </ul>
Micro-Prep Indication			Results Expected Q4 2018		<ul style="list-style-type: none"> <li>• Low residue diet prep label claim</li> <li>• Unlocks direct to patient marketing</li> </ul>

### Colon Cleanliness Directly Correlates to Quality of Exam

#### Primary Endpoint

Improvement in colon cleanliness (BBPS)


#### Secondary Endpoints

Patient satisfaction and quality metrics

# CLINICAL RESULTS INDICATE OUTSTANDING CLEANING PERFORMANCE

Study Prep: ~18 hour full liquid diet and Dulcolax®

% of Subjects Adequately Prepped According to BBPS Standard<sup>1</sup>



Boston Bowel Preparation Scale (BBPS) Score Before and After Pure-Vu®

Pure-Vu® Study	Before	After
Multicenter Study 1 (N=48)	5.0 ± 1.52	8.8 ± 1.14
Multicenter Study 2 (N=46)	2.8 ± 2.28	8.5 ± 0.84

BBPS is a scale of 0 (dirty) to 9 (pristinely clean)

Colon Before and After Pure-Vu®




# INCREASED CLEANLINESS CORRELATES TO REDUCED RISK OF CRC



Increased BBPS Score Increases Identification Rate of Adenomas Greater Than 5 mm<sup>1</sup>



Increases in ADR Correlates to Decrease in Risk of Interval Cancer<sup>2</sup>



## PURE-VU® ALIGNS PHYSICIAN WITH PATIENTS AND PAYERS

- Potential for Significant Cost Avoidance for Hospital In-patients
- Potential Path to Reimbursement for High Medical Need / Difficult to Prep Population
- Opportunity to Improve Patient Satisfaction and Quality of Exam
- Opportunity to Increase Revenue and Margins in ASC



# CLEAR PATHWAY TO BECOME STANDARD OF CARE

*Focused on sustainable long-term growth*

2018

2020

BEYOND

## **Market Development: today**

Driving clinical / health economic data  
Developing practice management model  
Building physician champions


## **Commercial Growth: 2019-2020**

Full market launch  
Scale manufacturing and logistics  
Direct-to-patient marketing

## **Market Dominance: 2021 and beyond**

Reimbursement for colonoscopy  
Global operations at full commercial scale  
Broad brand awareness and patient pull-through

## EXPECTED NEAR-TERM VALUE-DRIVING MILESTONES





## ROBUST INTELLECTUAL PROPERTY

Covers Innovative Portfolio of Technologies Rooted in Systems and Methods for Cleaning Body Cavities With or Without the Use of Endoscope

4

Issued patents in United States and Europe

11

Pending patents in United States

20

Pending patents outside United States

## \$17.5 Million Initial Public Offering in February 2018

### FINANCIAL PROFILE: NASDAQ: MOTS

Market Cap: \$75M<sup>1</sup>

Common Shares Outstanding: ~15.6M

Average Daily Volume: ~90K<sup>1</sup>

Cash Balance: ~\$20M<sup>2</sup>

## MANAGEMENT TEAM

### Mark Pomeranz, *Chief Executive Officer*

30 years of experience in the medical device industry with strong track record of success in both start-ups and in large multinational organizations

 svelte medical systems

 **Baxter**

### Andrew L. Taylor, MBA, *Chief Financial Officer*

Over 20 years of experience serving as a financial officer, operating executive and business advisor across start-ups, emerging growth and Fortune 500 companies in both the U.S. and abroad

 **AC LORDI**

### Hagit Ephrath, *VP, Clinical Regulatory and Health Economics*

Nearly 20 years of medical device experience focused on managing statistics, regulatory affairs, clinical and quality assurance activities through all phases of development

 CARMEL BIOSENSOR

### James Zardeskas, *VP, Quality Assurance*

Over 30 years of cross functional medical device experience at both startups and large organizations with focus in manufacturing and process development engineering

 **Boston Scientific**

### Gil Balog, *General Manager, Israel*

Extensive knowledge in product management, project management, product roadmap development, engineering, operations and production

  **OPTIMAL**

## BOARD OF DIRECTORS

### David Hochman *Chairman*

Director of Corbus, Adgero, Caliber, and BackBeat; Managing Partner, Orchestra Medical Ventures



### Gary Jacobs

Managing Director, Jacobs Investment Company

JACOBS INVESTMENT COMPANY



### Shervin Korangy

CFO and Chief Strategy Officer of Beaver-Visitec International



### Samuel Nussbaum

Former EVP, Clinical Health Policy & CMO of Anthem, Inc., one of the largest health benefits companies in U.S.



### Mark Pomeranz *Chief Executive Officer*

CEO, Motus GI



### Gary J. Pruden

Former Executive Vice President and Worldwide Chairman for the Johnson & Johnson Medical Devices group



### Darren Sherman

CEO of Caliber Therapeutics; Managing Partner, Orchestra Medical Ventures



## PHYSICIAN ADVISORY BOARD

### Gerald Bertiger, MD

Managing Partner and President of Hillmont, GI, P. C.; Section Chief of Gastroenterology and Director of the Endoscopy Unit at Chestnut Hill Hospital



### Steven A. Edmundowicz, MD, FASGE

Medical Director, Digestive Health Center, University of Colorado Hospital; Visiting Professor of Medicine, University of Colorado School of Medicine, Aurora, CO



### Prof. Ian Gralnek, MD, MSHS, FASGE

Chief, Ellen and Pinchas Mamber Institute of Gastroenterology; Ha'Emek Medical Center, Afula, Israel; Rappaport Faculty of Medicine Technion-Israel Institute of Technology



### Brian Jacobson, MD, MPH, AGAG, FASGE

Medical Director, Boston Accountable Care Organization Section of Gastroenterology Oncology, Boston Medical Center. Associate Professor, Boston University School of Medicine, Boston, MA



### David Lieberman, MD, FACP

Professor of Medicine, Chief, Division of Gastroenterology and Hepatology, Oregon Health and Science University, Portland, OR



### Ori Segol, MD

Director of Gastroenterology, Carmel Medical Center, Haifa, Israel



### Prof. Peter D. Siersema, MD, PhD, FASGE

Professor of Endoscopic Gastroenterology Oncology, Dept. of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, Netherlands



## INVESTMENT HIGHLIGHTS

Revolutionizing the large and growing GI endoscopy market

Targeting a multi-billion dollar market opportunity

Building a strong foundation of clinical and health economic data

Pathway to become standard of care

Highly-experienced management team with proven track record



Thank you

[INFO@MOTUSGI.COM](mailto:INFO@MOTUSGI.COM)

NASDAQ: MOTS

[www.motusgi.com](http://www.motusgi.com)

---

